Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More
ALEMBIC | STRIDES PHARMA SCIENCE | ALEMBIC/ STRIDES PHARMA SCIENCE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 60.5 | 23.1 | 262.2% | View Chart |
P/BV | x | 5.2 | 2.2 | 241.1% | View Chart |
Dividend Yield | % | 0.2 | 0.2 | 87.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
STRIDES PHARMA SCIENCE Mar-18 |
ALEMBIC/ STRIDES PHARMA SCIENCE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 1,147 | 6.3% | |
Low | Rs | 34 | 642 | 5.3% | |
Sales per share (Unadj.) | Rs | 4.7 | 317.2 | 1.5% | |
Earnings per share (Unadj.) | Rs | 6.1 | 7.8 | 77.8% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 25.1 | 24.9% | |
Dividends per share (Unadj.) | Rs | 0.20 | 2.00 | 10.0% | |
Dividend yield (eoy) | % | 0.4 | 0.2 | 168.9% | |
Book value per share (Unadj.) | Rs | 40.7 | 274.3 | 14.8% | |
Shares outstanding (eoy) | m | 267.03 | 89.50 | 298.4% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 11.3 | 2.8 | 399.5% | |
Avg P/E ratio | x | 8.7 | 114.0 | 7.6% | |
P/CF ratio (eoy) | x | 8.5 | 35.7 | 23.7% | |
Price / Book Value ratio | x | 1.3 | 3.3 | 39.9% | |
Dividend payout | % | 3.3 | 25.5 | 12.9% | |
Avg Mkt Cap | Rs m | 14,139 | 80,058 | 17.7% | |
No. of employees | `000 | NA | 2.5 | 0.0% | |
Total wages/salary | Rs m | 207 | 4,341 | 4.8% | |
Avg. sales/employee | Rs Th | NM | 11,325.8 | - | |
Avg. wages/employee | Rs Th | NM | 1,731.4 | - | |
Avg. net profit/employee | Rs Th | NM | 280.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 28,394 | 4.4% | |
Other income | Rs m | 370 | 941 | 39.4% | |
Total revenues | Rs m | 1,625 | 29,334 | 5.5% | |
Gross profit | Rs m | 111 | 3,965 | 2.8% | |
Depreciation | Rs m | 38 | 1,540 | 2.5% | |
Interest | Rs m | 2 | 1,962 | 0.1% | |
Profit before tax | Rs m | 442 | 1,403 | 31.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1,212 | -168 | -721.4% | |
Extraordinary Inc (Exp) | Rs m | 0 | -436 | 0.0% | |
Tax | Rs m | 24 | 97 | 24.6% | |
Profit after tax | Rs m | 1,630 | 702 | 232.1% | |
Gross profit margin | % | 8.9 | 14.0 | 63.4% | |
Effective tax rate | % | 5.4 | 6.9 | 78.2% | |
Net profit margin | % | 129.8 | 2.5 | 5,251.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 24,836 | 7.5% | |
Current liabilities | Rs m | 591 | 18,993 | 3.1% | |
Net working cap to sales | % | 101.6 | 20.6 | 494.0% | |
Current ratio | x | 3.2 | 1.3 | 241.5% | |
Inventory Days | Days | 94 | 71 | 132.8% | |
Debtors Days | Days | 74 | 113 | 64.8% | |
Net fixed assets | Rs m | 1,791 | 34,289 | 5.2% | |
Share capital | Rs m | 534 | 895 | 59.7% | |
"Free" reserves | Rs m | 10,324 | 23,651 | 43.7% | |
Net worth | Rs m | 10,858 | 24,546 | 44.2% | |
Long term debt | Rs m | 41 | 15,513 | 0.3% | |
Total assets | Rs m | 11,591 | 65,437 | 17.7% | |
Interest coverage | x | 260.9 | 1.7 | 15,211.4% | |
Debt to equity ratio | x | 0 | 0.6 | 0.6% | |
Sales to assets ratio | x | 0.1 | 0.4 | 25.0% | |
Return on assets | % | 14.1 | 4.1 | 345.7% | |
Return on equity | % | 15.0 | 2.9 | 524.8% | |
Return on capital | % | 15.2 | 6.9 | 220.3% | |
Exports to sales | % | 1.5 | 0 | - | |
Imports to sales | % | 21.0 | 0 | - | |
Exports (fob) | Rs m | 19 | NA | - | |
Imports (cif) | Rs m | 263 | NA | - | |
Fx inflow | Rs m | 19 | 15,697 | 0.1% | |
Fx outflow | Rs m | 264 | 735 | 35.9% | |
Net fx | Rs m | -244 | 14,962 | -1.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 1,871 | 12.6% | |
From Investments | Rs m | -224 | 5,826 | -3.8% | |
From Financial Activity | Rs m | -27 | -10,157 | 0.3% | |
Net Cashflow | Rs m | -15 | -2,615 | 0.6% |
Indian Promoters | % | 64.0 | 27.7 | 231.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 37.8 | 0.5% | |
FIIs | % | 9.7 | 8.6 | 112.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 26.1 | 25.9 | 100.8% | |
Shareholders | 54,701 | 56,241 | 97.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: SUVEN LIFE SCIENCES NEULAND LABS PIRAMAL ENTERPRISES FDC SUN PHARMA
Compare ALEMBIC With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.
For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More